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is overlap in the criteria to qualify for funding. Many countries consider drugs for 
additional funding when a drug can be used in more than one indication and can-
not be grouped to a specific DRG. Other criteria identified relate to, for example, 
drug prices and indications. Some countries grant additional reimbursement for 
drugs prior to assessment by a national reimbursement process, while others only 
grant additional reimbursement after the drug has been available for a certain 
period of time and funding decisions are based on historical data. In most countries, 
additional reimbursement is considered annually. Hospitals and expert groups can 
suggest additional reimbursement for expensive drugs to the responsible author-
ity. ConClusions: Many countries have adapted to the need for additional funding 
for expensive drugs, and have established systems to grant this funding to hospitals. 
There are differences in criteria to qualify for, and timelines for receiving, additional 
funding after drugs are launched.
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objeCtives: Initiatives aimed at improving both the quality and efficiency of United 
States health care are commonly grouped under the broad category of “pay-for-
performance” (P4P) programs. Typically these programs award bonuses to providers 
that attain pre-determined quality and cost goals, but may also impose financial 
penalties on those that fail to meet those goals. Fueled by the Affordable Care Act, 
P4P programs have recently expanded significantly within the public sector and 
are expected to grow. This project was designed to review Medicare P4P cost meas-
ures, discuss the implications for provider prescribing patterns, and recommend 
possible alternatives. Methods: Two P4P programs, both well known under the 
health reform law and having potential to impact a large portion of the Medicare 
population, were evaluated: 1) Accountable Care Organizations (ACO), and 2) the 
Physician Value Based Payment Modifier (VBPM). Each program’s cost measure 
components and calculation methodologies were isolated, described and evalu-
ated for the potential to influence prescribing patterns. Results: Cost measures 
for the ACO and VBPM programs are based on payments made under Medicare Part 
A (Hospital Insurance) and Medicare Part B (Supplemental Insurance) but do not 
include Medicare Part D (Prescription Drug Benefit) costs. Whether performance 
is measured against the provider’s historic costs, or compared to national bench-
marks, only Medicare Parts A and B costs are included. ConClusions: Medicare 
Part D costs are not included in the cost measure calculation, thereby eliminating 
prescription drug expense from the performance rating. This methodology may 
encourage providers to shift Part B drug costs to Part D, thus limiting patient access 
to therapies that may only be covered under Medicare Part B.
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objeCtives: To provide an up-to-date description and comparative analysis of pric-
ing and reimbursement policies in South-Eastern Europe (SEE), and to identify fac-
tors influencing reimbursement decisions. Methods: Payers and decision makers 
in Slovenia, Croatia, Romania and Bulgaria were interviewed by questionnaire. An 
additional literature survey covered country-specific legislation and publications 
(PubMed 2009–2014), and relevant documents from web sources including national 
hospital insurance funds, drug agencies, ministries of health, Eurostat, pharmacoeco-
nomic and outcomes research conference proceedings, the Organisation for Economic 
Co-operation and Development, and Business Monitor International. Results: The 
four countries spent 5.1%–8.8% of gross domestic product on health in 2012. Price 
controls are commonly used, applied via negotiation with marketing authorisation 
holders or indirectly through the application of copayments. Key policies are based 
on international and internal reference pricing. Bulgaria, Romania and Slovenia 
base pricing on the lowest manufacturing or retail price, while Croatia uses average 
pricing. Reimbursement requires demonstration of clinical and economical benefits 
over current standard therapy. When the importance of benefits are recognised and 
recommendations from reference health technology assessment authorities in 
Europe are published, budget impact analyses focusing on key drivers such as target 
population and price are applied. Cost containment mechanisms are also applied, 
including net price negotiation, rationing, decision postponement, payback, claw-
back and risk sharing, with the aim of protecting overall budgets. Legislative changes 
to pricing and reimbursement systems are very common. Out-of-pocket expenses 
in Romania and Bulgaria are among the highest in Europe, while the reimbursed: 
retail price difference is largely covered by supplementary insurance in Slovenia and 
Croatia. ConClusions: The middle/lower income SEE countries use reference pric-
ing, and have some of the lowest prices in the European Union. Reimbursement of 
innovative drugs is restricted, there are downward trends in pricing, and risk-sharing 
agreements based on outcomes are finance-driven.
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objeCtives: To gain a better understanding of the pricing and reimbursement pro-
cesses and evidence requirements at national, regional, and local levels with regards 
to a biologic obtaining a license in a second indication in the UK, France, Italy, and 
Spain. Methods: In countries with a largely national system (UK, France), five 
telephone interviews were conducted; as Spain and Italy also have local and regional 
systems, 17 and 18 interviews, respectively, were conducted. Stakeholders included 
payer-advising clinicians, hospital administrators and pharmacists, regional pay-
ers, and local payers. Results: In the UK and France, pricing and reimbursement 
is agreed at a national level, with few restrictions at regional and local levels. In the 
UK, NHS England is likely to be responsible for funding of new biologics and relies 
on guidance from NICE before adopting a product in a new indication; therefore, 
demonstrating cost-effectiveness is key. In France, the ASMR issued by the transpar-
ency commission is important; funding usually is through the groupe homogéne 
de séjour. In addition to demonstrating clinical benefits, pharmacoeconomic stud-
ies may be required for high-cost drugs. In contrast, in Italy, although AIFA needs 
to approve a new product on a national level, subsequent requirements vary by 
region and sometimes specific location. Similarly, in Spain, once approved nation-
ally, regions develop their own recommendations, and local decisions are made by 
hospital formularies. Evidence requirements in Italy and Spain vary at national, 
regional, and local levels. ConClusions: A biologic obtaining a license in a new 
indication must undergo the same procedure as a new product. The process and 
restrictions for biologics may be stricter than for other medications due to the 
perceived high cost. The level of national, regional, and local requirements and 
restrictions varies; it is important that appropriate evidence is submitted to deci-
sion makers at each level.
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objeCtives: Medical devices, together with pharmacotherapy are supportive treat-
ment of many acute and chronic diseases. The place of their dispensing and direct 
sale is the dispenser of medical devices. Many medical devices are reimbursed from 
public health insurance funds entirely, for others, particularly advanced functional 
types of medical devices, there must the patient participate on the price or he can 
buy them according own decision. Methods:  The target of the work was to analyse 
the data from paid databases of Slovak authority National Center for Health 
Information that collects the outputs of provided health care services. The most 
recent data were from 1.1. - 30.9.2014. Results: Referring to the Center for Health 
Information until 30.9.2013 there were 226 registered establishments that sell medical 
devices. Their specialization were dispenser of medical devices (n= 163), dispenser of 
orthopedic devices (n= 48) and dispenser of audioprotetic devices (n= 15). Expenditure 
of reimbursed medical devices from public health insurance funds amounted 
n-monthly packaging= 8,8mil and n-monthly value= 12,7 mil € . The highest shares had the 
group medical devices for incontinence and urinary retention (n-packages= 7,7 mil, 
n-packages%= 86.9, n-values= 3,9 mil € , n-value%= 30.9), the group plasters and bandag-
ing materials (n-packages= 0,5 mil, n-packages%= 6.1, n-values= 2,6mil € , n-value%= 10.2) and 
medical devices for ostomates (n-packages= 0,4 mil, n-packages%= 4.6, n-values= 1,6 mil € , 
n-value%= 8.1). direct sale of medical devices to the patients reached n-monthly packaging= 
 0, 9 mil and n-monthly value= 1,1mil € . The highest shares had the group medical devices 
for incontinence and urinary retention (n-packages= 5,7 mil, n-packages%= 50.3, n-values= 
2, 6 mil € , n-value%= 26.2), the group plasters and bandaging materials (n-packages= 3,5 
mil, n-packages%= 30.9, n-values= 2,0 mil € , n-value%= 20.4) and medical devices for 
diabetics (n-packages= 0,5 mil, n-packages%= 4.5, n-values= 0,7 mil € , n-value%= 7.3).  
ConClusions: Medical devices are reimbursed frompublic health insurance funds 
or paid by patient and their proportion constitutes 7: 1 in packages and 11: 1 in Eur.
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objeCtives: Troika’s measures to support Greece’s financial recovery have tar-
geted all sectors of economy including health care. Since 2012, policy reforms have 
changed the way health care is funded, managed and delivered, and how pharma-
ceuticals are priced, accessed and reimbursed. This study examines the changes 
to the Greek system and tries to understand the wider possible impact on global 
pricing and access strategies. Methods: To better understand the recent reforms 
we conducted a literature review of public domain sources, including the Greek 
Government Gazette, PubMed and other websites. Searches were conducted in 
English and Greek-language, and materials were translated into English. From our 
findings a road map diagram was developed, and this was validated by interviews 
with health policy experts. Results: Part of troika’s campaign to reduce public 
spending has seen the Greek government focus on pharmaceutical markets and 
introduce policies to contain costs. The drug budget for 2014 has been cut to 2 
billion euros, a billion lower than 2013. Considerable price cuts have been agreed 
on both novel and generic agents on top of clawbacks and rebates for high cost 
drugs. Prescribing is controlled through electronic prescription and physician budget 
caps. Introduction of price-volume agreements and risk sharing schemes are being 
considered, however the infrastructure to support implementation is still under 
development. Demonstrating value by health economics and outcomes research 
can still help manufacturers to achieve premiums. ConClusions: With a small 
population and an ever-decreasing expenditure on health care, it is tempting to 
overlook Greece when developing a product launch strategy. However, with Greek 
drug prices being referenced by several EU and non-EU countries, ignoring Greece 
may no longer be an option, especially when considering the indirect effect on the 
big EU5 prices. Understanding the reforms and assessing the impact on launch 
sequencing will be key in developing optimal pricing strategies.
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objeCtives: Switzerland’s regulation of prices for reimbursed drugs is based on 
referencing across countries and within the therapeutic class for products with 
comparators. The SwissHTA initiative involving all key stakeholders in the health 
care systems (sickness funds, industry, physicians, academia, Kantons) has pub-
lished consensus papers for new benefit criteria and measurements. Methods: 
A comparison was executed comparing the new proposed criteria against benefit 
assessments in HTA systems in Germany and the UK. Results: In terms of clinical 
benefit assessment the suggestion by SwissHTA follows accepted evidence-based 
methods. In comparison to Germany the Swiss approach suggests a pragmatic 
application by applying disease specific standards. This disease focus allows also 
accepting different levels of evidence given the characteristics of the disease. This 
pragmatic approach allows Swiss decision-makers accepting lower evidence levels 
at the time of launch (e.g. in case of comparison with non-Swiss standard-of-care) 
coupled with a post-reimbursement commitment. The Swiss method looks simi-
lar to the medical benefit application by NICE. In terms of health economic (HE) 
evaluations SwissHTA suggests focusing on technical efficiency instead of QALY 
comparisons across the whole system as in the UK. Such an approach avoids the 
application of arbitrarily defined cost-effectiveness thresholds. In Germany the HE 
focus is solely based on cost comparisons. In terms of decision-making in Germany 
the focus is based on an assessment of the available evidence against a theoreti-
cal maximum standard of evidence. In the UK coverage decisions are based on 
cost-effectiveness assessments allowing for context-specific adjustments. In the 
SwissHTA recommendation a multi-criteria decision-making should be applied 
with an equal focus on all key aspects (e.g. clinical benefit, public relevance, social 
preferences, etc.). ConClusions: In comparison to HTA systems in Germany and 
UK the SwissHTA recommendations seems to be more pragmatic and would follow 
a broader multi-criteria decision making approach.
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objeCtives: FDA has long recognized that dramatic increase in adverse event 
reports due to medical devices and recalls may reflect quality flaws. While some 
of this increase can be explicated by FDA’s greater outreach emphasizing reporting 
requirements, failures in product design and manufacturing process cause more 
than half of all product recalls. Therefore, FDA’s concern regarding low quality prod-
ucts remains. In the EU, medical device pre-market quality is assured by CE mark 
authorization. This regulation is the prerequisite for market registration also for 
Turkey. However, due to heterogeneity and complexity of devices, manufacturers, 
imported devices and multiple use environments, there is strong need for post-
market quality assurance. Methods: This study investigates whether post-market 
quality assurance (measured by less adverse events/better health outcomes) can be 
applied through local reimbursement policies. First, it is investigated whether there 
are reimbursement rules in Europe acting as post-market quality assurance. Then, 
a comparison is made with Turkey’s existing reimbursement scheme. Results: 
Our comparative analysis reveals only Belgium and France implement quality or 
brand based reimbursement rules. In Turkey, there is no quality based reimburse-
ment scheme; however current reimbursement application guideline requirements 
may act as a gate keeper for lower quality products. Our Results show in addition 
to pre-market regulations, post-market quality can be assured by local reimburse-
ment authorities. ConClusions: There are several opportunities to improve 
quality assurance and reduce risk across medical device industry; i.e. enhancing 
visibility of comparative quality to harness market forces and increasing the col-
laboration between stakeholders. From health policy perspective, implementation 
of new value based reimbursement models require providers to prove that they’re 
meeting quality standards and benefitting patients while cutting costs. Therefore, 
while value based payment contracts are still in their infancy in Europe and Turkey, 
they will have a direct impact on the assurance of continued medical device quality.
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objeCtives: In Germany, Scotland and the Netherlands, the manufacturer’s 
submission is assessed by the HTA bodies; G-BA, SMC and NZi. In Germany, the 
submitted evidence is used to assess the drug’s additional benefit, followed by 
price-rebate negotiations with the GKV-Spitzenverband. In Scotland and the 
Netherlands, the submitted evidence is evaluated for reimbursement decision. 
This study aims to compare factors that influence the reimbursement recom-
mendation by SMC and NZi, the additional benefit by G-BA and the rebate by 
GKV-Spitzenverband. Methods: Three databases were created consisting of 
463 SMC applications, 262 NZi evaluations and 68 G-BA decisions. Logistic regres-
sion analyses were conducted to assess the impact of the submitted evidence 
on the recommendation by SMC and NZi and the effect of variables on the addi-
tional therapeutic benefit by G-BA. The impact of variables on the rebate was 
examined through linear regression analysis. Results: In Scotland, 57% of the 
applications received positive recommendation and the NZi recommended 83% of 
the submissions. In Germany, 60.3% of the products demonstrated an additional 
benefit. In Scotland, the multivariate analyses showed that the performance of a 
cost-minimization analysis and beneficial cost-effectiveness outcomes were the 
strongest positive predictors of the recommendation. In the Netherlands, univari-
ate analyses showed that the decision was significantly affected by whether the 
product under assessment was a life-saving intervention and the inclusion of 
(positive) economic evidence. In Germany, univariate analyses demonstrated that 
the therapeutic indication and the overall survival benefit, along with improved 
morbidity and adverse events meaningfully influenced the benefit assessment. 
Analysis showed that the rebate was significantly reduced by 13% for products 
that demonstrated additional benefit. ConClusions: Even though reimburse-
ment submission requirements of Scotland and the Netherlands look similar, 
SMC weights the cost-effectiveness outcomes more, while NZi focuses on the 
variables related to additional clinical benefit; variables that also significantly 
influence G-BA’s decision.
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objeCtives: The Pharmaceutical Market Restructuring Act (AMNOG) has brought 
a sustainable change to the reimbursement of new drugs in Germany. The G-BA 
assesses the additional benefit of the drug, compared to an appropriate therapy. 
AMNOG law is perceived to be one of the toughest drug evaluation process in Europe. 
In France the high authority for health (HAS) assesses the level of improvement of 
actual benefit (IAB). The objective of this study was to compare the additional benefit 
score issued under AMNOG law to IAB scores granted by the HAS. Methods: All 
G-BA’s additional benefit scores until June 1st 2014 and HAS IAB score were com-
pared. Results: In Germany, a total of 76 completed early benefit assessments. 
From the best available score perspective, the G-BA assessed the additional benefit 
as considerable in 20% of drugs assessed (score 2), as minor in 30% of drugs assessed 
(score 3), as unquantifiable in 8% of drugs assessed (Score 4) and as none in 38% 
of drugs assessed (Score 5). No drug has been granted a major additional benefit 
(score 1) and 4% of drugs were directly allocated to a reference price group. In France, 
the transparency committee granted a major improvement in 0.2% of cases (IAB 
I), an important improvement in 1.3% of cases (IAB II), a moderate improvement 
2.5% of cases (IAB III), a minor improvement in 9,2% of cases (IAB 4) and no clini-
cal improvement in 86.8% of cases (IAB V). ConClusions: This study shows that 
the G-BA assigned an additional benefit (scores from 1 to 4) to more than half of 
drugs whereas the HAS granted an additional benefice rating to less than 14% of 
case. This study suggests that there is a more favourable benefit rating in Germany 
than in France.
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objeCtives: Biosimilars have the potential to revolutionise the health care land-
scape by realising cost savings over originator biologics and thus increasing access 
to innovative medicines. The biosimilars marketplace in the UK and Ireland is 
relatively new, however the landscape is rapidly developing. The objective of this 
analysis was to map the HTA status of biosimilars in the UK and Ireland to provide 
insight for stakeholders involved in the assessment of new biosimilars. Methods: 
The HTA status of all EMA authorised biosimilars was identified by searching the 
websites of all four HTA agencies in the UK and Ireland, namely, NICE, the SMC, the 
AWMSG, and the NCPE. All previously assessed medicines and on-going technology 
appraisals were screened for the inclusion of biosimilars using the non-proprietary 
(common name) and proprietary (brand) names. Results: Sixteen (84%) of the 
nineteen biosimilars submitted to the EMA have been authorised, eleven of which 
(69%) have been considered by HTA agencies. The SMC has approved 100% of the 
biosimilars it has considered (n= 7); the largest positive reimbursement rate amongst 
all HTA agencies considered. The AWMSG has considered the largest number of 
biosimilars (n= 11), of which five, (45%) received a positive reimbursement status. 
Both NICE and the NCPE have approved one biosimilar, however three additional 
biosimilars are currently being considered by NICE. ConClusions: The reim-
bursement status of biosimilars in the UK and Ireland is not consistent across HTA 
agencies. The timing of HTA submissions to different HTA agencies may play an 
important factor in the reimbursement status of biosimilars given that this land-
scape is relatively new and assessment processes vary. Marketing authorisation 
holders for biosimilars may want to consider the strategic importance of submitting 
evidence to each of the HTA agencies in the UK and Ireland, and the impact timing 
may have on the uptake of their biosimilar.
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objeCtives: Identifying the right patient population, comparator and endpoints is 
key to increase the likelihood of reimbursement. Manufacturers do not always agree 
with payers’ views on these items. Disagreement may lead to funding rejection. We 
assessed the rate of mismatches between manufacturers and NICE and their impact 
on the final appraisal outcome. Methods: All manufacturer submissions (MS) 
from January 2011 until June 2014 were reviewed. For these submissions, the initial 
proposed scope, the manufacturer’s comments, and the final scope and appraisal 
outcome were analysed. All changes to the initial scope suggested by the manu-
facturer were recorded and their impact on final outcome investigated. Results: 
In the time period reviewed there were 101 MS of which 7 were suspended and 
not included in our analysis, while comments were not available for another 18. 
Manufacturer comments are published for 76 MS. The manufacturer disagreed on 
≥ 1 section of initial scope in 93% (71/76) of MS. The areas where manufacturers and 
NICE disagreed most commonly are the comparator(s) (43/71; 61%) and population 
(40/71; 56%) to be assessed. The final scope implemented all and some of the manu-
facturer’s comments in 56% (40/71) and 28% (29/71) of submissions, respectively. 
